Placental Pathology and Inflammatory Factor Analysis of OAPS
- Conditions
- Antiphospholipid Syndrome in Pregnancy
- Interventions
- Other: no intervention
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05378516
- Locations
- 🇨🇳
PekingUPH, Pekin, China
A Cohort Study of Environmental Endocrine Disrupting Chemicals and Female Reproductive Health
- Conditions
- IVF
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT05373290
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia
Phase 2
Not yet recruiting
- Conditions
- Immune Thrombocytopenia
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05369377
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
Phase 2
Not yet recruiting
- Conditions
- Immune Thrombocytopenia
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05369364
Small Molecule LCDM and GV Oocyte
- Conditions
- Assisted Reproduction
- Interventions
- Other: Small molecule LCDM
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT05356429
The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Phase 2
- Conditions
- Immune ThrombocytopeniaBlood Coagulation DisordersThrombocytopeniaPhysiological Effects of Drugs
- Interventions
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05353673
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Multiomics Tumor Evolution Model of NSCLC
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05352035
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
The Combination of Prednisone and Recombinant Human Thrombopoietin for Treatment of Immune Thrombocytopenia in Pregnancy
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05333744
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, China
Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 390
- Registration Number
- NCT05326659
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Phase III Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Atopic Dermatitis
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT05326672
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath